Search results
Results from the WOW.Com Content Network
The CDC has regulated the laboratories which may possess, use, or transfer select agents within the United States under the SAP since 2001. The SAP was established to satisfy requirements of the USA PATRIOT Act of 2001 and the Public Health Security and Bioterrorism Preparedness and Response Act of 2002, which were enacted in the wake of the September 11, 2001 attacks and the subsequent 2001 ...
The agents in this list are often combined into chemotherapy agent for polychemotherapy (combination chemotherapy). For example, the CHOP regimen consists of cyclophosphamide, doxorubicin, vincristine and prednisone. Besides chemotherapy, medical oncology (pharmacotherapy for cancer) includes several noncytotoxic classes of therapy, such as ...
The Division of Select Agents and Toxins (DSAT) of the Centers for Disease Control and Prevention is responsible for the Select Agent Program and the Etiologic Agent Import Permit Program. They inspect the laboratories of more than 300 organizations approved to use and transfer select agents , and put regulations in place to minimize risk in ...
This list of over 500 monoclonal antibodies includes approved and investigational drugs as well as drugs that have been withdrawn from market; consequently, the column Use does not necessarily indicate clinical usage. See the list of FDA-approved therapeutic monoclonal antibodies in the monoclonal antibody therapy page.
CDC and MSF staff preparing to enter an Ebola treatment unit in Liberia, August 2014. Within the division are two programs: the Federal Select Agent Program (FSAP) and the Import Permit Program. The FSAP is run jointly with an office within the U.S. Department of Agriculture, regulating agents that can cause disease in humans, animals, and plants.
As a result, the entire antibody, linker and cytotoxic (anti-cancer) agent enter the targeted cancer cell where the antibody is degraded into an amino acid. The resulting complex – amino acid, linker and cytotoxic agent – is considered to be the active drug. In contrast, cleavable linkers are detached by enzymes in the cancer cell. The ...
Non-small cell lung cancer, oesophageal cancer, uterine cervical cancer, head and neck cancer and urothelial cancer: Nephrotoxicity, myelosuppression and nausea and vomiting (30-90%). Oxaliplatin: IV: Reacts with DNA, inducing apoptosis, non-cell cycle specific. Colorectal cancer, oesophageal cancer and gastric cancer
This list focuses on the hazard linked to the agents. This means that while carcinogens are capable of causing cancer, it does not take their risk into account, which is the probability of causing a cancer, given the level of exposure to this carcinogen. [2] The list is up to date as of January 2024. [3]